Policy & Regulation
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
19 November 2020 - - An mRNA-based COVID-19 vaccine candidate, BNT162b2, from US-based biopharmaceutical company Pfizer Inc. (NYSE: PFE) and German biotechnology company BioNTech SE (NASDAQ: BNTX) has met all of the study's primary efficacy endpoints, the companies said.

The companies said they reached this conclusion after conducting the final efficacy analysis in their ongoing Phase 3 study.

Analysis of the data indicates a vaccine efficacy rate of 95% (p